Patent · US Active

Methods for modulating C9ORF72 expression

US9963699B2 · kind B2 · utility

15Cited by

18References

28Claims

0Family size

Assignees

Ionis Pharmaceuticals, Inc. · US
LUDWIG INSTITUTE FOR CANCER RESEARCH LTD · GB
The Regents of the University of California · US

Inventors

C. Frank Bennett · Carlsbad, US
Susan M. Freier · San Diego, US
Frank Rigo · Carlsbad, US
Don W. Cleveland · Alameda, US
Clotilde Lagier-Tourenne · Winchester, US
John M. Ravits · Village of La Jolla, US
Michael W. Baughn · Village of La Jolla, US

Key dates

Filing date	Oct 15, 2013
Grant date	May 8, 2018
Priority date	—
Expiry date	Oct 15, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2310/341
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

Disclosed herein are methods for reducing expression of C90RF72 mRNA and protein in an animal with C90RF72 specific inhibitors. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Such C90RF72 specific inhibitors include antisense compounds. Examples of neurodegenerative diseases that can be treated, prevented, and ameliorated with the administration C90RF72 specific inhibitors include amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), corticalbasal degeneration syndrome (CBD), atypical Parkinsonian syndrome, and olivopontocerellar degeneration (OPCD).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.